Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Stamford Health is committed to stopping the spread of COVID-19. For details regarding the resumption of services and reopening of facilities, how to help and FAQs, visit here. 

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallelgroup Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome (CSL112-3001) AEGIS II

Study Details

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

CSL112-3001/AEGIS II

Learn More

ClinicalTrials.gov NCT number
NCT03473223

Principal Investigators

  • David Hsi, MD
Contact
Maryanne Ducey, DC, RN at 203-358-8879
or officeofresearch@stamhealth.org

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.